Skip to main content
SpringerLink
Log in

Paclitaxel-based therapy no better than cisplatin and 5-FU for operable esophageal cancer

  • Research Highlight
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paclitaxel-based therapy no better than cisplatin and 5-FU for operable esophageal cancer. Nat Rev Clin Oncol 5, 7–8 (2008). https://doi.org/10.1038/ncponc0992

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0992

  • Springer Nature Limited

Search

Navigation